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Peroxisomes and mitochondria are the main intracellular sources for reactive oxygen species. At the same time, both organelles are
critical for the maintenance of a healthy redox balance in the cell. Consequently, failure in the function of both organelles is causally
linked to oxidative stress and accelerated aging. However, it has become clear that peroxisomes and mitochondria are much more
intimately connected both physiologically and structurally. Both organelles share common ﬁssion components to dynamically
respond to environmental cues, and the autophagic turnover of both peroxisomes and mitochondria is decisive for cellular
homeostasis. Moreover, peroxisomes can physically associate with mitochondria via speciﬁc protein complexes. Therefore, the
structural and functional connection of both organelles is a critical and dynamic feature in the regulation of oxidative
metabolism, whose dynamic nature will be revealed in the future. In this review, we will focus on fundamental aspects of the
peroxisome-mitochondria interplay derived from simple models such as yeast and move onto discussing the impact of an
impaired peroxisomal and mitochondrial homeostasis on ROS production, aging, and disease in humans.
1. Introduction
Oxidative stress is causally linked to accelerated aging and
aging-related diseases [1]. In eukaryotic cells, mitochondria
and peroxisomes are the main ROS contributors [2, 3]. At
the same time, both organelles are equipped with their own
ROS scavenging repertoire of enzymes. Mitochondria and
peroxisomes are metabolically linked because they share
common pathways such as the fatty acid β-oxidation. How-
ever, both organelles are much more intimately regulated
with respect to ROS homeostasis and the clearance of dys-
functional organelles. Here, we will focus on our current
knowledge of mitochondrial and peroxisomal pro- and anti-
oxidant functions, their coordinated turnover by autophagic
pathways, and their functional and physical interactions.
Investigation in the yeast model is contributing fundamental
insights into the mechanisms of quality control of peroxi-
somes and mitochondria. Therefore, we will compare the
dynamics of both organelles and its impact on cell sur-
vival and health in yeast and mammalian cells throughout
the review.
2. Pro- and Antioxidant Functions of
Peroxisomes
Peroxisomes are versatile organelles found in most eukary-
otic cells. The name peroxisome has been originally intro-
duced for a cellular organelle which contains at least one
H2O2-producing oxidase and the H2O2-detoxifying enzyme
catalase [4]. Today, we know that peroxisomal function goes
far beyond the metabolism of reactive oxygen species. Perox-
isomes contain more than 50 diﬀerent enzymatic activities,
which shape important metabolic and anabolic functions,
including fatty acid oxidation and lipid biosynthesis. As they
share an oxidative metabolism together with mitochondria,
they are key organelles in the cellular homeostasis of ROS
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[5, 6]. Although the variability of the metabolic activities con-
tained by peroxisomes of diﬀerent organisms or tissues is
considerable, their universal functions are the oxidative
metabolism of fatty acids and the degradation of H2O2 by
catalases [7]. Thus, peroxisomes are both sources and sinks
of ROS and account for a great part of oxygen consumption
and ROS production (up to 35%) in metabolically active tis-
sues such as the liver [4, 8]. Peroxisomes are much more
dynamic organelles than anticipated, and the impact of the
dynamic regulation of their size, abundance, morphology,
and function in response to environmental stimuli or during
development has only recently been addressed [9–11]. Given
the dynamic nature of peroxisomes and their central role in
fatty acid oxidation, an eﬃcient quality control of this organ-
elle is required to avoid oxidative damage and premature
aging [3, 5, 12].
The oxidative degradation of fatty acids takes place in
peroxisomes and mitochondria (Figure 1). However, the
compartmentalization of fatty acid oxidation pathways
between these two organelles is variable in diﬀerent organ-
isms. Budding yeast, for example, degrades fatty acids exclu-
sively in peroxisomes via β-oxidation, which implies the
removal of two carbons from the fatty acid carboxyl terminus
[13]. The ﬁrst step in this process is catalyzed by acyl-CoA
oxidases, which reduce O2 to H2O2. The end product of β-
oxidation in yeast, acetyl-CoA, is transformed to acetyl-
carnitine by peroxisomal carnitine acetyl-CoA transferases
and shuttled into mitochondria to fuel the Krebs cycle and
respiration. In human cells, mitochondria and peroxisomes
cooperate in diﬀerent routes of fatty acid oxidation [14]. Here,
fatty acids with shorter chain lengths (C6-C20) are oxidized by
β-oxidation in mitochondria, where the ﬁrst step is catalyzed
by acyl-CoA dehydrogenases coupled to the mitochondrial
electron transport and not to H2O2 production. However,
fatty acids with longer chain lengths (>C20) or dicarboxylic
fatty acids have to be degraded by the peroxisomal β-oxida-
tion pathway. Additionally, 3-methyl-branched fatty acids
are exclusively metabolized in human peroxisomes by the
process of α-oxidation, which represents an additional source
of the ROS H2O2 originating from these organelles. In the
human case, β-oxidation is not necessarily carried out to
completion in peroxisomes; hence, the ﬁnal product is a
shortened fatty acyl-CoA, which is shuttled to mitochondria
in the form of the corresponding fatty acyl carnitine conju-
gate. It is worth noting that ROS production by mammalian
peroxisomes is not limited to the fatty acyl-CoA oxidases of
the β-oxidation pathway. Additionally, oxidases participat-
ing in glyoxylate metabolism, amino acid catabolism, or
the oxidation of polyamines are potential ROS sources of
the peroxisome [15].
Peroxisomes contain several antioxidant systems, which
are important for ROS homeostasis of this highly oxidative
organelle (Figure 1). Since the β-oxidation pathway directly
produces H2O2, the detoxifying catalase activity is of central
importance for the redox balance of the organelle [16, 17].
It has been shown in yeast that peroxisomal catalase is
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Figure 1: Pro- and antioxidant functions of peroxisomes and mitochondria in yeast and mammalian cells. Peroxisomes play important
roles in the oxidative degradation of fatty acids. The peroxisomal fatty acid oxidation pathways are schematically depicted for budding
yeast (a) and mammalian cells (b). Mitochondrial pro- and antioxidant functions and their interconnection with peroxisomes are
summarized. ROS-generating and ROS-scavenging functions are highlighted for both organelles. FA= fatty acid; bFA= branched fatty
acid; VLFA= very long fatty acid; SMLFA= small, medium, and long fatty acids; FA-CoA= fatty acyl coenzyme A; ETC= electron
transport chain; Gpx = glutathione peroxidase; Grx = glutaredoxin; GR and Glr = glutathione reductase; Sod = superoxide dismutase;
GSH= reduced glutathione; GSSG= oxidized glutathione; Prx = peroxiredoxin; Trx = thioredoxin; Trr and TrxR= thioredoxin reductase;
DH=dehydrogenase; I to V =mitochondrial respiratory complexes I–V.
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required also for the tolerance to externally added H2O2,
which suggests that peroxisomes are generally important
for cellular ROS detoxiﬁcation [18]. An additional peroxi-
somal antioxidant activity has been described in yeast as
the glutathione peroxidase Gpx1, whose activity is generally
required for a proper peroxisomal biogenesis [19]. Also in
mammalian cells, catalase is the predominant antioxidant
activity of peroxisomes. However, several other ROS detoxi-
fying are known in higher eukaryotes to contribute to perox-
isomal redox balance, which include superoxide dismutases,
peroxiredoxins, glutathione S-transferases, and epoxide
hydrolases [5].
The importance of peroxisomes in the maintenance of a
healthy redox balance has been derived from situations,
which interfere with a normal peroxisomal function and bio-
genesis. Artiﬁcial stimulation of peroxisomal biogenesis by
the long-term exposure to peroxisomal proliferators causes
oxidative liver damage and ROS imbalances in general in
rodents [20, 21], most likely by the uncompensated induction
of ROS-generating peroxisomal enzymes [22]. However,
stimulated peroxisomal proliferation seems to reduce ROS
levels in murine neurons [23]. Moreover, the loss of peroxi-
somes increases the apoptotic damage in the cerebellum
and neurodegeneration [24, 25], and a deﬁciency in human
catalase activity increases the susceptibility to aging-related
diseases such as diabetes, cancer, or atherosclerosis [26].
Moreover, catalase mutants show phenotypes of accelerated
aging in the Caenorhabditis model [27]. In yeast, loss of
catalase function modulates the lifespan depending on the
metabolic activity of peroxisomes [18]. Thus, peroxisomal
(together with mitochondrial) activity in maintaining the
cellular redox state is generally important for cell survival
and health [28, 29].
3. Pro- and Antioxidant Functions of
Mitochondria
Mitochondria have been traditionally described as the cellu-
lar power-house as they are the main contributors of energy
through oxidative phosphorylation and the biosynthesis of
ATP. Structurally, they contain two biologically diﬀerent
membrane systems: the outer membrane containing the
intermembrane space and the inner membrane containing
the mitochondrial matrix. The diﬀerent electron transport
chain (ETC) protein complexes are embedded in the inner
membrane, which is heavily folded into the cristae structure
[30]. Apart from regulating the energy metabolism of the
eukaryotic cell, mitochondria are involved in many other
fundamental processes, such as the control of the cell cycle
or the induction or prevention of cell death [31–33].
Generation of ATP by the mitochondrial oxidative phos-
phorylation is based on the reduction of molecular oxygen,
which can produce toxic byproducts such as the superoxide
radical (O2
_) or hydrogen peroxide (H2O2). Only complex
IV (cytochrome c oxidase) of the ETC is able to fully reduce
molecular oxygen to water and therefore has an antioxidant
function in the ETC, while mainly complex I (NADH ubiqui-
none oxidoreductase) and complex III (ubiquinol-cyto-
chrome c oxidoreductase) contribute to superoxide radical
formation due to incomplete O2 reduction [34]. These ROS
can trigger the formation of even more harmful secondary
ROS such as the hydroxyl radical (.OH), which are supposed
to be responsible for the main oxidative damage derived
from mitochondrial activity [35, 36]. Electron leakage from
mitochondrial electron transport chains is now recognized
as one of the most important intracellular sources of ROS
including hydroxyl radicals [37]. Mitochondria possess
their own antioxidant systems, which consist of various
ROS-scavenging enzymes and low molecular antioxidants
[38, 39]. Primary antioxidant enzymes are superoxide dismu-
tases (SOD), which reduce superoxide radicals to hydrogen
peroxide. Two types of SOD can be found in mammalian
mitochondria: manganese superoxide dismutase (SOD2) in
the mitochondrial matrix and copper/zinc superoxide dis-
mutase (SOD1) in the intermembrane space [40–42]. Detox-
iﬁcation of mitochondrial H2O2 can be achieved by the
activity of glutathione peroxidases (GPx) and glutaredoxins
(GRx). At least two GPx isoforms have been identiﬁed in
the mammalian mitochondria, GPx1 and GPx4 [43, 44],
and two Grx isoenzymes are active in mitochondria, Grx2
and Grx5 [45]. During this reaction, glutathione is oxidized,
which has to be reduced by mitochondrial glutathione reduc-
tase (GR) with the help of the mitochondrial NADPH pool.
Additionally, hydrogen peroxide can be reduced by mito-
chondrial peroxiredoxins (Prx) coupled to the oxidation of
thioredoxins (Trx), which are ﬁnally recycled at the expense
of NADPH by Trx reductases (TrxR). In the mammalian
mitochondria, at least the isoenzymes Prx3, Prx5, and Trx2
have been described [46–50]. Among the nonenzymatic anti-
oxidants found in the mammalian mitochondria, the high
NADPH pool, vitamin C, and coenzyme Q have been
reported with important functions in ROS elimination
[51–53]. As opposed to peroxisomes, signiﬁcant catalase
activity is absent from the mammalian mitochondria. Yeast
mitochondria also contain a full set of antioxidant systems
based on glutathione or thioredoxin with the enzymes
Gpx2, Grx2, Glr1, Prx1, Trx3, and Trr2 [54]. Also in yeast,
the Sod1 Cu/Zn- and the Sod2 manganese-superoxide
dismutases are the primary ROS-reducing enzymes in mito-
chondria [55, 56]. Additionally, and diﬀerent to the situation
in mammalian cells, the peroxisomal catalase Cta1 can also
be found inside the yeast mitochondria [57].
The free radical theory of aging ﬁrst postulated that the
accumulation of cellular damage caused by free radicals was
a decisive driving force in the process of aging and in the
determination of a lifespan [58]. A major prediction derived
from this theory was that the supplementation with
antioxidants or genetic manipulation of endogenous ROS-
scavenging systems would have a beneﬁcial eﬀect on the life-
span of the organism. However, no conclusive results were
obtained by studies of this type in general [59–64], which
led to a revision of the original hypothesis in a form of the
mitochondrial-free radical theory [65]. Here, mitochond-
rially generated free radicals were supposed to have a major
eﬀect on aging, and thus it was proposed that reinforcement
of mitochondrial antioxidant systems had lifespan extension
eﬀects. On the contrary, mitochondrial damage or insuﬃ-
cient ROS-scavenging activity of mitochondria could lead
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to lifespan shortening. A large body of evidence has accumu-
lated, which supports this hypothesis [66–68]. Artiﬁcial
targeting of catalase to mitochondria extends the lifespan of
mice [69]. Similarly, the mitochondria-targeted antioxidant
SkQ1 has lifespan extension eﬀects in several rodent models
[70]. On the contrary, mouse models, with mutations in the
mitochondrial DNA polymerase gamma, have a shorter life-
span and manifest several phenotypes of accelerated aging
[71]. Furthermore, the accumulation of damage in the mito-
chondrial DNA (mtDNA) caused in these mouse models has
been reported to favor apoptosis and age-related diseases
[72] and can be reverted by mitochondria-targeted catalase
[73]. Moreover, deﬁciencies in Mn-superoxide dismutase
activity increases oxidative stress and promotes aging in
Drosophila [74–76]. Yeast has very eﬃciently contributed
to reveal physiologically relevant determinants of lifespan
and health span in higher organisms [77, 78]. Also in this
simple model, mitochondria have been identiﬁed with an
important role in the establishment of lifespan [79]. Speciﬁ-
cally, yeast sodmutants are known to critically interfere with
longevity [80]. Having found that mitochondrial ROS pro-
duction is a driving factor of aging, a growing number of
studies now intend to reduce ROS production by the targeted
delivery of antioxidants to the mitochondria [1]. These
approaches include the use of mitochondria-directed redox
agents to detoxify mitochondrial ROS [81] or modulators of
mitochondrial electron transport and leakage to avoid mito-
chondrial ROS [82]. These strategies are beyond the scope
of this review; hence, the interested reader might consult
summaries made by excellent recent revisions [68, 83, 84].
It is important to note that ROS might not always trigger
fatal oxidative damage within a cell. On the contrary, low
ROS concentrations have important biological functions
related to signaling and stress resistance [85–87]. It has been
increasingly clear in the last years that oxidative stress is able
to actually promote longevity, which has led to the theory of
mitochondrial hormesis. Here, stimuli such as calorie restric-
tion or exercise are supposed to trigger adaptations, which
lead to the reinforcement of endogenous antioxidant
systems, increased stress tolerance, and subsequently slow
down the aging process [88, 89]. There are many experimen-
tal ﬁndings in diﬀerent model systems including yeast,
Caenorhabditis or Drosophila, which are in line with the
mitohormesis hypothesis [90, 91]. Inhibition of respiration,
for example, increases the lifespan of nematodes dependent
on the production of mitochondrial ROS [92]. Calorie
restriction and especially glucose restriction partially induce
mitochondrial metabolism and prevent aging from yeast to
ﬂies [93, 94]. It has been demonstrated in Caenorhabditis
that reduced sugar intake induces mitochondrial respiration
and ROS production, which are necessary for lifespan exten-
sion, and this beneﬁcial eﬀect is reverted by antioxidants [95].
In yeast, several interventions including the inhibition of
nutrient-sensing protein kinases or dietary restriction cause
an extended lifespan [96]. These eﬀects have been shown to
depend on mitochondrial activity in general or speciﬁc
mitochondrial ROS-scavenging activities [97–100]. Taken
together, mitochondrial ROS balance is decisive for the mod-
ulation of longevity and we will continue to summarize how
mitochondrial and peroxisomal activity might change during
the process of aging and in age-related diseases.
4. Compromised Function of Peroxisomes and
Mitochondria during Aging
The investigation of the detrimental function of peroxisomal
dysfunction in the process of aging has traditionally lagged
behind mitochondria, which were considered the major
source of oxidative stress-related senescence. However, it is
much more considered now that a misregulated peroxisomal
ROS balance is important in the occurrence of age-related
diseases [3, 101, 102]. Recently, it has been shown that a deﬁ-
ciency in peroxisomal ROS clearance actually aﬀects mito-
chondrial function. Speciﬁcally, inhibition of peroxisomal
catalase activity negatively modulates the redox balance in
mouse mitochondria [103] and human ﬁbroblast [104].
Moreover, a localized oxidative damage to peroxisomes leads
to mitochondrial fragmentation and cell death [105, 106].
These results reﬂect the intimate relation of both organelles
in the maintenance of the cellular redox balance and further-
more suggest that peroxisomal dysfunction can subsequently
damage mitochondria. Therefore, peroxisomes can act at the
forefront in the initiation of cellular oxidative damage and
aging [3]. Accordingly, several reports support that peroxi-
somal function continuously declines during aging. In
cultured human cells, it has been shown that catalase is
increasingly excluded from peroxisomes after repeated cell
passage. At the same time, old cells accumulate more dys-
functional peroxisomes which raise cellular ROS levels and
ultimately might accelerate aging [107]. In line with these
results is the ﬁnding that in Caenorhabditis the abundance
of many peroxisomal proteins decays during aging. Impor-
tantly, this aﬀects the Pex5 importer of peroxisomal matrix
proteins [108]. Pex5 function has been found to be regulated
by the redox state of the organelle [109, 110]. Thus, the
decline of peroxisomal protein import by oxidative stress,
including the import of antioxidants, might be a trigger for
senescence. Additionally, it has been shown that yeast perox-
isome proliferation is regulated by the redox state of the
organelle [19]. Oxidative stress might inhibit yeast peroxi-
somal biogenesis via multiple targets, such as Pex5 or Pex11
[109, 111–113]. Finally, interference with peroxisomal ﬁssion
increases the lifespan of yeast cells [114]. Taken together,
maintaining functional peroxisomes emerges as an impor-
tant determinant of the cellular lifespan. The relevant mech-
anisms of peroxisomal homeostasis will be discussed in the
following section.
A large body of experiments has demonstrated that mito-
chondrial dysfunction is an important trigger for cellular
senescence, which contributes to aging in addition to other
prosenescence stimuli [115–118]. Although it is clear that
dysfunctional mitochondria accumulate in senescent cells
and that this is a major driving force for accelerated aging
[119–121], it is less understood how mitochondria become
dysfunctional during the aging process [122, 123]. Mitochon-
drial defects which accumulate in older cells range from an
increased mitochondrial mass, a decrease of respiratory cou-
pling, less eﬃcient ATP production during respiration, loss
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of respiratory complex I function, and increased mitochon-
drial ROS production [117, 118].
Importantly, there is increasing evidence that misregu-
lated ROS production is an important trigger for mitochon-
drial dysfunction in the context of several age-related
diseases. Cardiomyopathy in the old age, for example, is
accompanied by an impairment of oxidative phosphoryla-
tion in heart mitochondria [87, 124]. Consequently, the rate
of ROS production increases with age especially in cardiac
mitochondria [125]. Similarly, an ineﬃcient mitochondrial
energy metabolism has been linked to cardiovascular diseases
[126, 127]. In order to explain this decline in mitochondrial
function, several mechanisms have been suggested, for exam-
ple, an impaired biogenesis of the organelle, increased mito-
chondrial uncoupling, or the accumulation of mt-DNA
mutations [128–130]. Mitochondrial dysfunction has been
broadly implied in age-related neurodegenerative diseases
[131–133]. In the particular case of Alzheimer’s disease, the
accumulation of the toxic aggregates of the unprocessed β-
amyloid peptide is known to inhibit the mitochondrial elec-
tron transport chain, cause ROS overproduction, and induce
mitochondria-mediated cell death [134–138]. Additionally,
the accumulation of mt-DNA aberrations and failures in
the dynamic regulation of mitochondrial morphology by
ﬁssion have been linked to Alzheimer’s disease [139–141].
Parkinson’s disease is another neurodegenerative disorder
where mitochondrial dysfunction has been identiﬁed as a
major driving force. Several genes have been associated with
familial Parkinson, and most of these PARK loci are func-
tionally related with mitochondria [142]. PARK1 for exam-
ple encodes α-synuclein, which can inhibit mitochondrial
fusion [143]. Mutations in PARK7 aﬀect DJ-1 function caus-
ing defects of mitochondrial respiratory complex I, ROS
overproduction, and a loss of mitochondrial membrane
potential [144, 145]. PARK8 encodes the LRRK2 protein
kinase, whose function is needed for proper oxidative phos-
phorylation activity and mitochondrial ﬁssion [146, 147].
PARK2 and PARK6 encode Parkin and PINK1 (PTEN-
induced kinase 1), which are involved in the correct turnover
and degradation of dysfunctional mitochondria by mito-
phagy [148, 149]. The mechanisms of autophagic removal
of excess or malfunctioning mitochondria and peroxisomes
will be described in the following section.
Mitochondria form dynamic networks, whose morphol-
ogy changes in response to stress and nutritional stimuli
and damage [150, 151]. Several independent experimental
evidences exist showing that changes in mitochondrial
dynamics are intimately linked to senescence and accelerated
aging [152]. During aging, mitochondrial ﬁssion is reduced,
which leads to mitochondrial elongation [153]. It has been
shown that inhibition of the proﬁssion protein FIS1 or the
E3 ubiquitin ligase MARCH5, which positively regulates
mitochondrial ﬁssion, induces senescence via mitochondrial
elongation [154, 155]. In yeast, the pharmacological repres-
sion of mitochondrial ﬁssion leads to a lifespan extension
[154, 156]. These results indicate that mitochondrial ﬁssion
is needed for a normal cellular lifespan. This is in agreement
with the ﬁnding that hyperelongated mitochondria have
lower membrane potentials and excessively produce ROS
[153, 154]. Additionally, the reinforcement of mitochondrial
ﬁssion by the overexpression of FIS1 can reduce age-related
phenotypes [153]. Importantly, mitochondrial ﬁssion is
needed for eﬃcient clearance of defective mitochondria via
mitophagy, which could additionally explain the antiaging
eﬀect of the ﬁssion process [157, 158]. In a reverse manner,
oxidative stress alters mitochondrial morphology via the
modulation of several proteins involved in mitochondrial
dynamics and this phenomenon has been linked to cancer
progression [159–161]. Exogenous ROS eﬃciently inhibit
mitofusins (Mfn1 and Mfn2) in human ﬁbroblasts and mus-
cle myoblasts inducing mitochondrial ﬁssion and membrane
depolarization [162, 163]. In yeast, oxidative stress promotes
mitochondrial fragmentation via the stimulation of the
assembly of the mitochondrial ﬁssion machinery composed
of Mdv1, the Dnm1 GTPase, and the Fis1 mitochondrial ﬁs-
sion proteins [164].
Another important question is whether the asymmetric
inheritance of mitochondria of diﬀerent qualities or activities
modulates the aging process. This phenomenon has been
extensively studied in the yeast model of replicative aging
[165]. During cell divisions, proaging components such as
damaged or dysfunctional mitochondria are retained in the
older mother cell and not transmitted to the young daughter
cell [166]. Speciﬁc mitochondrial tether proteins such as
Mmr1 have been identiﬁed, which actively retain highly oxi-
dative mitochondria in the mother cell. Consequently, inter-
ference with this asymmetric mitochondrial distribution by
deletion of Mmr1 shortens the yeast lifespan [167]. Addi-
tional anchor proteins such as Mfb1 have been identiﬁed
now, which guarantee the remaining of highly functional
mitochondria in the mother cell [168]. Interestingly, the
unequal distribution of mitochondria from the mother to
daughter cell is conditioned by mitochondrial dynamics
since it is impaired in mitochondrial fusion mutants [169].
Taken together, the fusion/ﬁssion process of mitochondria
(and peroxisomes) is important for the maintenance of a
healthy redox balance and lifespan. The quality control
of both organelles via autophagic mechanisms is of key
importance to maintain both mitochondria and peroxi-
somes functional.
5. Quality Control of Peroxisomes and
Mitochondria by Autophagy and the
Impact on Health
The number, activity, and quality of peroxisomes are dynam-
ically adapted and controlled in the cell [170]. An important
mechanism to eliminate dysfunctional or superﬂuous perox-
isomes consists in a speciﬁc autophagy termed pexophagy
[171]. The mechanisms which assure the engulfment of spe-
ciﬁc peroxisomes in autophagosomes and their subsequent
degradation in vacuoles (fungi) or lysosomes (mammals)
have been especially elucidated in the yeast model [172].
Here, pexophagy has been intensively studied in response
to nutritional changes from respiratory to fermentative
growth conditions, which implies the proteolytic removal of
excess peroxisomes [172]. The key step in the initiation of
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pexophagy is the formation of a preautophagosomal struc-
ture at the surface of the organelle [173–176] (Figure 2).
Several Atg proteins are coordinated in this process termed
cytoplasm-to-vacuole targeting; however, the Atg11 cytosolic
adaptor protein is the physical link of the organelle to be
degraded and the autophagosome in the case of both perox-
isomes and mitochondria [175, 176]. Atg11 contacts the per-
oxisome via a speciﬁc adaptor protein at the peroxisomal
surface. In budding yeast, the speciﬁc adaptor for pexophagy
is Atg36, which directly interacts with the peroxisomal Pex3
protein and the core phagosomal components Atg11 and
Atg8 [177, 178]. One way to induce pexophagy is through
the phosphorylation of Atg36 by the Hrr25 casein kinase
homolog [179]. Hrr25 phosphorylates a speciﬁc serine resi-
due (S97) in the Atg36 adaptor, which triggers its interaction
with Atg11 but not with Pex3 [179]. Therefore, phosphoryla-
tion of Atg36 by Hrr25 is a switch in the initiation of pexo-
phagy by allowing the interaction of the peroxisome with
the central autophagosomal machinery [179]. Peroxisomes
have their own ﬁssion system to allow an autonomous prolif-
eration of the organelle. In yeast, the dynamin-related small
GTPases Dnm1 and Vps1 together with the ﬁssion protein
Fis1 are required for peroxisomal ﬁssion [180–182]. It has
been shown recently that peroxisomal ﬁssion is required for
pexophagy [183]. Moreover, the Atg11 adaptor protein inter-
acts directly with Dnm1 and Vps1 [183]. Taken together, the
Atg11 mediated recruitment of the preautophagosomal
structure at strategic sites of the peroxisome via Pex3, and
the ﬁssion machinery seems to be the initial step for marking
peroxisomes for proteolytic degradation. It is less understood
whether and how pexophagy serves to eliminate dysfunc-
tional peroxisomes. However, it has been shown in yeast that
artiﬁcially created catalase aggregates are cleared in a process
that depends on peroxisomal ﬁssion and pexophagy [184].
Additionally, peroxisomal protein import defects have been
shown to increase the rate of pexophagy [185]. These results
suggest that the autophagic removal of damaged peroxi-
somes with increased ROS production could be an impor-
tant mechanism to maintain a correct redox balance in the
cell [172]. Consistent with this idea is the ﬁnding that per-
oxisomal proliferation seems to be regulated by the redox
state of the organelle [19] and that abiotic stress such as salt
stress induces the number of peroxisomes via Dnm1 and
Vps1 [186].
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Figure 2: Mechanisms of autophagic removal of peroxisomes and mitochondria. In the upper panel, pexophagy mechanisms are depicted for
budding yeast (a) andmammalian cells (b). In yeast, pexophagy is induced by the Hrr1 kinase which phosphorylates the Atg36 adaptor. Atg36
contacts the Pex3 peroxisomal receptor, the ﬁssion machinery (Dnm1, Vps1), and the autophagosomal adaptor Atg11. In mammalian cells, a
dysfunctional peroxisome and general ROS increase activate the ATM kinase, which phoshorylates the Pex5 receptor. Pex5 is additionally
targeted by ubiquitination via the starvation-inducible Pex2. Modiﬁed Pex5 interacts with the autophagosomal adaptors NBR1 and p62. In
the lower panel, mitophagy mechanisms are depicted for budding yeast (left) and mammalian cells (right). In yeast, starvation induces
mitophagy via casein kinase 2 (CK2), which phosphorylates the Atg32 receptor. Modiﬁed Atg32 interacts with the Atg11 autophagosomal
adaptor, which also contacts the mitochondrial ﬁssion machinery (Dnm1). In mammalian cells, mitochondrial dysfunction triggers the
exposure of PINK1 at the organelle surface. PINK1 phosphorylates and activates the Parkin ubiquitin ligase, which marks outer
mitochondrial membrane proteins. PINK1 additionally phosphorylates polyubiquitin chains at mitochondria, which leads to recognition
by the autophagosomal adaptor proteins Optineurin (OPTN) and NDP52. P = phosphorylation; Ub= ubiquitination.
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The mechanisms of pexophagy in mammalian cells are
only beginning to be unraveled [187, 188]. Here, selective
autophagy of peroxisomes relies on cytosolic adaptor pro-
teins such as p62 or NBR1, which recognize ubiquitinated
cargo proteins and direct them to the autophagosome [189]
(Figure 2). Pex5 is the peroxisomal receptor which upon ubi-
quitination triggers the process of pexophagy [190, 191]. This
process can be stimulated upon external oxidative stress or by
the pharmacological induction of peroxisomal fatty acid oxi-
dation and involves the ATM kinase [191, 192]. Activated
ATM inhibits signaling through the mammalian TOR
pathway and marks Pex5 for pexophagy by phosphorylation
[193]. Subsequently, Pex5 is ubiquitinated, and p62-
dependent autophagy is initiated [191]. An E3 ubiquitin
ligase responsible for Pex5 ubiquitination has been recently
found with Pex2 at least upon nutrient starvation conditions
[194]. Taken together, these ﬁndings suggest that an excess of
ROS produced at peroxisomes triggers the process of speciﬁc
pexophagy to maintain a healthy redox balance in mamma-
lian cells.
The removal of excess or damaged mitochondria by
selective autophagy or mitophagy is an essential cellular
homeostasis mechanism. In yeast, this process has been
heavily studied upon nutrient starvation conditions, for
example, upon depletion of a N-source or in the stationary
growth phase. These approaches have revealed many molec-
ular insights of mitophagy; however, it remains unclear
whether mitophagy in yeast actually degrades dysfunctional
organelles [195]. Of central importance is the mitochondrial
mitophagy receptor protein Atg32, which is localized at the
outer mitochondrial membrane [196, 197]. Upon induction
of mitophagy by starvation, Atg32 is phosphorylated by
casein kinase 2 (CK2) at a speciﬁc serine (S114) residue
[198]. Phosphorylation of Atg32 triggers its interaction with
the cytosolic Atg11 adaptor protein. Therefore, this step is
considered the initial signal in the targeting of mitochondrial
to the preautophagosomal structure. Interestingly, there are
at least two additional kinases which have been reported to
be necessary for Atg32 phosphorylation, the Hog1 and Slt2
MAP kinases [199, 200]. Although both kinases cannot
directly phosphorylate, the Atg32 receptor, the involvement
of both kinases in stress signaling, could indicate a possible
regulation of mitophagy by cellular stress stimuli additionally
to nutrient shortage. Although still a matter of debate, there
are experimental indications which suggest that mitophagy
in yeast depends on mitochondrial ﬁssion. Generally, the
mitochondrial ﬁssion proteins Fis1, Dnm1, Mdv1, and Caf4
seem to require for eﬃcient mitophagy [157, 158, 201]. Spe-
ciﬁcally, during mitophagy, Atg11 directly targets the mito-
chondrial Dnm1 ﬁssion protein [158]. This suggests that
mitophagy takes place close to the mitochondrial ﬁssion
apparatus which would be necessary to separate the mitopha-
gic cargo from the rest of the mitochondrial network [157].
Additional insights into the speciﬁc origins of mitophagy
have been recently revealed by the ﬁnding that speciﬁc con-
tact sites between the ER and mitochondria, the so called
ERMES (ER mitochondria encounter structure), are neces-
sary for mitophagy [202]. Thus, the initiation of mitophagy
might require a close contact between the mitochondrial
ﬁssion apparatus and the ER at strategic sites. It is less under-
stood whether mitophagy in yeast is necessary to avoid cellu-
lar damage by dysfunctional mitochondria or whether it is
activated upon oxidative stress. However, it has been
reported that autophagic removal of excess mitochondria
upon nutrient starvation is required to decrease intracellular
ROS levels [203].
In mammalian cells, mitophagy has been intensively
studied upon conditions which damage mitochondria by
counteracting and eliminating their normal membrane
potential [204] (Figure 2). In fact, loss of the mitochondrial
membrane potential is one of the main triggers of mitophagy
in mammalian models. Modulation of the mitochondrial
shape is another important step in mitophagy, and inhibition
of mitochondrial ﬁssion impairs the sequestration of dam-
aged mitochondria by autophagosomes [205, 206]. This sug-
gests that ﬁssion of the organelle, which is often induced by
cellular stress, is an important mechanism to segregate and
eliminate damaged mitochondria from the otherwise healthy
network. Failure in the execution of mitophagy surveillance
pathways clearly impairs the cellular homeostasis. This has
been demonstrated for the key regulators of mitophagy,
PINK1 (PTEN-induced kinase), and Parkin, whose mutation
can cause Parkinson’s disease [207, 208]. PINK1 is a mito-
chondrial serine/threonine kinase encoded by the PARK6
locus [208], while Parkin is a cytosolic E3 ubiquitin ligase
encoded by PARK2 [209]. Both proteins function in the same
mitophagic pathway with PINK1 acting upstream of Parkin
[210, 211]. Upon normal cell homeostasis, PINK1 is
imported into mitochondria dependent on the mitochondrial
membrane potential. In healthy mitochondria, it is cleaved
by PARL at the inner mitochondrial membrane, thereby
restricting its activity [212–214]. Loss of the mitochondrial
membrane potential inhibits PINK1 import and provokes
its accumulation at the outer mitochondrial membrane,
where it recruits Parkin [215–217]. This is considered the
key step to mark dysfunctional mitochondria for selective
degradation. Once exposed at the mitochondrial surface,
PINK1 forms larger aggregates, which stimulate PINK1
activity by autophosphorylation [218, 219]. Subsequently,
the mitophagic pathway is initiated by PINK1 phosphoryla-
tion of both Parkin and ubiquitin in a positive feedback reg-
ulation. The phosphorylation of Parkin by PINK1 is
necessary for its mitochondrial targeting and for its E3 ubiq-
uitin ligase activity [215, 216, 220–223]. Furthermore, PINK1
phosphorylates ubiquitin, and phosphorylated ubiquitin
seems to be the true targeting signal for Parkin [224–226].
Indeed, it has been recently revealed that Parkin accumula-
tion at damaged mitochondria requires phosphorylated
ubiquitin chains at the mitochondrial surface [227–229].
Ubiquitination of outer mitochondrial membrane proteins,
most importantly of the mitofusins Mfn1/2, ﬁnally triggers
the physical segregation of the damaged mitochondrial
parts and degradation via autophagosomes [230–232].
The nature of the autophagy receptors which would rec-
ognize ubiquitinated damaged mitochondria has been con-
troversial. However, a recent study discards the pexophagy
receptors p62 or NBR1 and speciﬁcally implies Optineurin
and NDP52 in PINK1/Parkin-mediated mitophagy [233].
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Thus, phospho-ubiquitin at the surface of damaged mito-
chondria is the signal to recruit the NDP52 and Opti-
neurin receptors, which in turn contact with components
of the autophagy pathway such as ULK1 or LC3 to engage
in the autophagic degradation of the dysfunctional mito-
chondria [234, 235].
It is important to note that mammalian cells apparently
use diﬀerent mitophagy pathways upon diﬀerent stimuli. It
has been demonstrated in mouse and human cells that oxida-
tive stress is a sensitive mitophagy trigger, which reinforces
the idea that the autophagic removal of damaged mitochon-
dria is a physiologically relevant mechanism of cell homeo-
stasis [236]. Apart from the PINK1/Parkin system, which
responds to a loss of mitochondrial membrane potential,
the Bcl2-L-13 protein (yeast Atg32 ortholog), the NIX/
BNIP3L, and the FUNDC1 mitochondrial outer membrane
proteins have been involved in diﬀerent types of mitophagy.
Bcl2-L-13 seems to mediate mitophagy and mitochondrial
fragmentation upon ETC damage [237], NIX/BNIP3L is
involved in mitochondrial clearance during erythrocyte dif-
ferentiation [238, 239], while FUNDC1 responds to hypoxic
conditions [240]. It remains unclear to what degree these
diﬀerent mitophagy receptors act separately in the process
of mitochondrial homeostasis.
6. Physiological and Physical Interaction of
Peroxisomes and Mitochondria
In mammalian cells, peroxisomes and mitochondria func-
tionally cooperate in the oxidative degradation of fatty acids
by β-oxidation (see Figure 1). Both organelles have diﬀerent
but partially overlapping substrate speciﬁcities with regard to
the chemical structure of the fatty acid to be metabolized.
Therefore, peroxisomes and mitochondria cooperate in the
homeostasis of lipids. The details of this metabolic coopera-
tion have been summarized in excellent recent reviews
[241, 242]. It is important to note that both organelles share
metabolic pathways apart from β-oxidation, for example in
the detoxiﬁcation of glyoxylate or in the degradation of spe-
cial fatty acids via α-oxidation [241, 243]. Also, it can be
assumed that extensive peroxisomal α-oxidation depends
on the ATP supply from the mitochondrial respiratory chain.
More importantly, it has been recently shown that there is an
intimate crosstalk between peroxisomes and mitochondria in
the homeostasis of intracellular ROS beyond the fact that
both organelles are important sources and sinks for ROS as
detailed above. It had been known that weakening the perox-
isomal catalase activity either by pharmacological treatment
or caused by the decreased protein import capacity triggered
elevated oxidative stress and reduced enzyme activity at
mitochondria [104, 107, 244]. The use of peroxisomally
directed inducers of oxidative stress has then revealed that
mitochondria indeed are downstream of peroxisomally
generated ROS [101], which is manifested by mitochondrial
fragmentation and cell death [105, 106]. It has been
suggested that mitochondrial oxidative damage is caused by
lipid peroxidation originated in peroxisomes arguing against
a simple diﬀusion of peroxisomal ROS to mitochondria. The
mechanisms of the peroxisome-mitochondria ROS interplay
are currently unknown; however, interorganelle contact sites
could explain this much more intimate relation of peroxi-
somes and mitochondria.
In the yeast model, the functional and physical interac-
tions of peroxisomes with mitochondria have been studied
intensively in recent years. As outlined above, fatty acid β-
oxidation occurs exclusively in peroxisomes of budding
yeast. Therefore, acetyl-CoA from peroxisomes has to be
channeled into mitochondria via the carnitine shuttle and
thus a direct contact of both organelles should favor this
exchange of metabolites. Indeed, it has been shown that yeast
peroxisomes preferentially localize close to speciﬁc mito-
chondrial sites which also contain contacts to the ER [245].
Recently, a possible physical tether between peroxisomes
and mitochondria has been suggested by the interaction of
the Pex11 protein involved in the biogenesis of the organelle
with the mitochondrial Mdm34 protein [246] (Figure 3).
Since Mdm34 is one of the structural components of the
mitochondria-ER tether ERMES [247], this ﬁnding opens
up the possibility that at least in yeast peroxisomes and
mitochondria are physically connected at speciﬁc contact
sites with the ER [248]. Recent evidence suggests that
peroxisome-mitochondria contact sites might also exist in
mammalian cells [249]. Since peroxisomes and mitochondria
share components of their ﬁssion machineries and the ﬁssion
of both organelles is important for their autophagic turnover,
it is possible that this three-way contact is structurally impor-
tant for the regulated turnover and therefore the ROS
homeostasis of both organelles. Additionally, the mitochon-
dria peroxisome interaction might be regulated dynamically
to modulate ROS homeostasis, the interchange of metabo-
lites or the respiratory eﬃciency. In this respect, it has been
Mitochondria 
Peroxisome 
Mdm34 Pex11 Mdm10 
Mmm1 Mdm12 
ER 
ERMES 
ROS balance
Metabolite exchange
Respiration efficiency 
? 
Figure 3: Overview of the yeast peroxisome-mitochondria contact
site. The ERMES (endoplasmic reticulum mitochondria encounter
structure) tethers mitochondria to the ER, but additionally
establishes a contact between mitochondria and peroxisomes
through the Mdm34-Pex11 interaction. The mitochondria-
peroxisome tether might have dynamic functions in the regulation
of ROS homeostasis, metabolite exchange between the two
organelles, or the modulation of respiratory eﬃciency.
8 Oxidative Medicine and Cellular Longevity
recently shown that the number of peroxisomes attached to
the mitochondrial network increases upon cellular stress
such as high salinity, which is known to also increase cellular
ROS levels [186].
7. Conclusions
We know that peroxisomes and mitochondria are the crucial
organelles in the homeostasis of eukaryotic ROS levels. Per-
oxisomes have traditionally lagged behind the importance
of mitochondria in the production and detoxiﬁcation of
intracellular oxidative stress; however, this diﬀerence has
largely disappeared in the past years. Current investigation
is now deciphering the functional interplay of both organelles
in the propagation and avoidance of oxidative damage in the
cell. Peroxisomal and mitochondrial oxidative stress are inti-
mately linked. Moreover, the dynamic ﬁssion of both organ-
elles shares structural components, and the turnover of
damaged peroxisomes and mitochondria as a mechanism to
reduce intracellular oxidative stress will still be an important
ﬁeld of investigation. From a structural viewpoint, we are
only beginning to understand howmolecular tethers between
peroxisomes and mitochondria, most likely via the ER, can
contribute to interorganelle communication and coordinated
quality control of both organelles. Therefore, investigation of
the peroxisome-mitochondria connection and its regulation
by stress will continue to contribute essential knowledge of
how the redox homeostasis is maintained in young, environ-
mentally challenged and aged eukaryotic cells.
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